Ceribell, Inc. (CBLL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$24.41+0.41%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Operating losses reduce from -$20.75 million in 2026-Q1: metric not reported.
Ceribell raised revenue guidance to $112-$116 million for 2026. Revenue grew from $20.49M in 2025-Q1 to $26.49M in 2026-Q1. Gross profit improved from $18.68M in 2025-Q2 to $23.12M in 2026-Q1. These show progress in sales and profit growth.
Operating losses widened to -$20.75M in 2026-Q1 from -$14.60M in 2025-Q4. The company is still losing money. Cost control is weak despite revenue growth.
The market expects about 33% revenue growth next year. Our fair value is near $11.85, close to the current price. We see risk from ongoing losses and cost issues.
Breaks if: Gross profit falls below $23.12 million in 2026-Q1
Ceribell aims to improve its gross profit, which has shown consistent growth over recent quarters.
Breaks if: Operating loss worsens beyond -$20.75 million in 2026-Q1
Focus on reducing operating losses through expense management and operational efficiencies.
Stated as a priority in 3 of last 3 quarters. Operating expenses increased from $33.6 million in 2025-Q4 to $45.9 million in 2026-Q2, while net loss grew from $13.6 million to $19.3 million. Despite management focus, operating losses have increased due to investments and legal costs, indicating limited progress in reducing losses.
“Operating expenses were $45.9 million in 2026-Q2, net loss was $19.3 million.”
“Operating expenses were $43.9 million in 2026-Q1, net loss was $19.7 million.”
“Operating expenses were $33.6 million in 2025-Q4, net loss was $13.6 million.”
Breaks if: Revenue falls below $112 million in FY26
Raise full-year 2026 revenue guidance reflecting growth from new accounts and increased utilization in existing accounts.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $21.2 million in 2025-Q2 to $28.1 million in 2026-Q2, a 33% increase. Management raised full-year 2026 revenue guidance from $111-$115 million in 2025-Q4 to $114-$117 million in 2026-Q2. The trajectory is delivering with consistent revenue growth and upward guidance revisions.
“Ceribell is raising its revenue guidance for the full year 2026 to a range of $114 million to $117 million”
“Ceribell is raising its revenue guidance for the full year 2026 to a range of $112 million to $116 million”
“Ceribell expects revenue for the full year 2026 to be in the range of $111 million to $115 million”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving operations and reducing losses. The current thesis state indicates mixed results, with management making progress on revenue and gross profit but struggling with operating losses.
The market seems to have priced in a low level of fragility, with a justified valuation despite recent earnings misses. There is a notable expectations gap, suggesting that the market anticipates some recovery but remains cautious.
Management is on track with revenue growth and improving gross margins, but operating losses have increased, indicating challenges in controlling costs. The near-term risk is elevated, especially given the company's history of consecutive earnings misses.
The long-term thesis hinges on management's ability to maintain revenue growth while addressing operating losses. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping outcomes.
In the next 1 to 3 years, CBLL's performance will depend on its operational improvements and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company increased its revenue guidance for 2026, which supports the thesis. However, the latest earnings report showed a miss, which weakens the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.